{"id":"argx-119-iv","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARGX-119 IV works by binding to CD70, a protein involved in the activation of immune cells. This binding leads to the depletion of CD70-expressing immune cells, which are thought to contribute to autoimmune diseases. By reducing the activity of these cells, ARGX-119 IV aims to alleviate symptoms and slow disease progression.","oneSentence":"ARGX-119 IV is a monoclonal antibody targeting CD70.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:04.403Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of generalized myasthenia gravis"}]},"trialDetails":[{"nctId":"NCT07287982","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy","status":"RECRUITING","sponsor":"argenx","startDate":"2025-12-19","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":60},{"nctId":"NCT06436742","phase":"PHASE1","title":"A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-09-24","conditions":"Congenital Myasthenic Syndrome, CMS","enrollment":16},{"nctId":"NCT05670704","phase":"PHASE1","title":"A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants","status":"COMPLETED","sponsor":"argenx","startDate":"2023-02-21","conditions":"Healthy Volunteers","enrollment":112}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARGX-119 IV","genericName":"ARGX-119 IV","companyName":"argenx","companyId":"argenx","modality":"Biologic","firstApprovalDate":"","aiSummary":"ARGX-119 is an antibody modality. It is also known by the synonyms 3B2G2M1-HLGG1 LALADELK and LALADELK.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}